32 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
to in the biopharmaceutical community as small molecules, but our BiDAC degraders tend to be larger than traditional small molecule therapeutics. We have selected … supporting our local community in their efforts to bridge the opportunity gap for underserved communities. With assistance from our Diversity, Equity
ARS
z70ahkwf
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
v0pnmdxf74ah3hdtvrow
18 Apr 23
Preliminary proxy
7:59am
424B4
fmzsl21wm054yh
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
52ifx2i 87miu0y2x3f
19 May 21
Draft registration statement
12:00am